NCT04229628

Brief Summary

To develop and implement quality improvement programs for the treatment and management of hypertension and diabetes,and preventing and controlling hypertension and diabetes-related diseases in Chinese community. This program will use data collection, analysis, feedback, and process improvement to extend the use of evidence-based guidelines throughout the healthcare system and improve patient care of hypertension and diabetes in Chinese community.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
100,000

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Jan 2020

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 1, 2020

Completed
11 days until next milestone

First Submitted

Initial submission to the registry

January 12, 2020

Completed
6 days until next milestone

First Posted

Study publicly available on registry

January 18, 2020

Completed
12 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 31, 2020

Completed
3 years until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2023

Completed
Last Updated

January 18, 2020

Status Verified

December 1, 2019

Enrollment Period

1 year

First QC Date

January 12, 2020

Last Update Submit

January 12, 2020

Conditions

HypertensionDiabetes Mellitus

Outcome Measures

Primary Outcomes (2)

  • Proportion of community hypertension patients receiving treatment as Chinese guideline recommended

    Proportion of community hypertension patients receiving treatment as Chinese guideline recommended at the time of enrollment

    at the time of enrollment

  • Proportion of community diabetes mellitus patients receiving treatment as Chinese guideline recommended

    Proportion of community diabetes mellitus patients receiving treatment as Chinese guideline recommended at the time of enrollment

    at the time of enrollment

Interventions

No special interventionOTHER

No special intervention

Eligibility Criteria

Sexall
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Hypertension Diabetes mellitus

You may qualify if:

  • In accordance with the diagnosis of essential hypertension;
  • In accordance with the diagnosis of type 2 diabetes mellitus.

You may not qualify if:

  • Non-type 2 diabetes patients
  • Secondary hypertension
  • Non-hypertensive patients
  • Type 1 diabetes or other types of diabetes

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Guangdong Provincial People's Hospital

Guangzhou, Guangdong, 510080, China

RECRUITING

Biospecimen

Retention: SAMPLES WITHOUT DNA

This study will collect 10 mL whole blood samples from subjects at one or more study visits. The whole blood will be processed to plasma, serum and stored for testing.

MeSH Terms

Conditions

HypertensionDiabetes Mellitus

Condition Hierarchy (Ancestors)

Vascular DiseasesCardiovascular DiseasesGlucose Metabolism DisordersMetabolic DiseasesNutritional and Metabolic DiseasesEndocrine System Diseases

Study Officials

  • Feng Ying-qing, PhD

    Guangdong Provincial People's Hospital

    STUDY DIRECTOR

Central Study Contacts

Feng Ying-qing, PhD

CONTACT

+862083827812651792209@qq.com

Study Design

Study Type
observational
Observational Model
CASE ONLY
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

January 12, 2020

First Posted

January 18, 2020

Study Start

January 1, 2020

Primary Completion

December 31, 2020

Study Completion

December 31, 2023

Last Updated

January 18, 2020

Record last verified: 2019-12

Locations

CN(1)